Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)

Inclusion Criteria: * Male or female subjects with type 2 diabetes mellitus of from 20 to 65 years of age. * Patients who have not achieve the clinical target of the glycemic control (less than 7.0% in HbA1c). * Patients who received the diet therapy, the exercise therapy or the following anti-diabetic drugs in addition to the diet and/or exercise therapy (up to two drugs) with dosage stable for 8 weeks prior to entry. * Sulfonylurea (Glymepiride 2mg/day or less, Glibenclamide 1.25mg/day or less, Gliclazide 40mg/day or less) * Thiazolidine (Actos) * Biguanide (Metformin, Buformin) * alpha-glucosidase inhibitor (Voglibose, Miglitol, Acarbose) * DPP4 inhibitors (Sitagliptin, Linagliptin, Anagliptin, Teneligliptin, Alogliptin, Saxagliptin) * Informed consent to participate in the study prior to any study procedures. Exclusion Criteria: * Type 1 diabetes mellitus * Moderate or severe renal dysfunction (eGFR\<45 ml/min/1.73m2 or hemodialysis) * Severe hepatic insufficiency (AST and/or ALT \>3x upper limit of normal) * Adrenal insufficiency or pituitary gland dysfunction * Malnourishment, starvation, irregular dietary intake, poor dietary intake, debilitating condition or a severe muscle movement * Volume depleted patients; concomitant medication such as loop diuretics. * Excessive alcohol intake (\>60g daily) * SGLT2 inhibitors such as dapagliflozin are already administered * Contraindication with dapagliflozin * Start a new medication of statins, fibrates, ezetimibe or probucol within a month * Females who are likely to be pregnant, during pregnancy or lactating * Participants in other clinical trials * Inability to communicate and comply with all study requirements.